Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-996-5252
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees130
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions
What is Kala Pharmaceuticals' stock symbol?
Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."
How were Kala Pharmaceuticals' earnings last quarter?
Kala Pharmaceuticals Inc (NASDAQ:KALA) issued its earnings results on Thursday, May, 9th. The company reported ($0.75) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.75). The business had revenue of $1.39 million for the quarter, compared to the consensus estimate of $0.96 million. View Kala Pharmaceuticals' Earnings History.
When is Kala Pharmaceuticals' next earnings date?
What price target have analysts set for KALA?
6 equities research analysts have issued 12-month price objectives for Kala Pharmaceuticals' shares. Their predictions range from $11.00 to $51.00. On average, they anticipate Kala Pharmaceuticals' stock price to reach $21.50 in the next year. This suggests a possible upside of 284.6% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals.
What is the consensus analysts' recommendation for Kala Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals.
What are Wall Street analysts saying about Kala Pharmaceuticals stock?
Here are some recent quotes from research analysts about Kala Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts and the female reproductive systems. Kala Pharmaceuticals, Inc. is based in Waltham, United States. " (5/14/2019)
- 2. HC Wainwright analysts commented, "Our 12-month price target is derived from a market value of the firm at $495M, which includes a discounted cash flow-based asset value of $570M for INVELTYS (100% probability of success) and KPI-121 0.25% (65% probability of success), with a 15% discount rate and 0.5% terminal growth rate, excluding $75M debt." (12/27/2018)
Has Kala Pharmaceuticals been receiving favorable news coverage?
News articles about KALA stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Kala Pharmaceuticals earned a news impact score of 1.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the company's share price in the next several days. View News Stories for Kala Pharmaceuticals.
Who are some of Kala Pharmaceuticals' key competitors?
Some companies that are related to Kala Pharmaceuticals include Aptorum Group (APM), Odonate Therapeutics (ODT), Vanda Pharmaceuticals (VNDA), Mallinckrodt (MNK), Kura Oncology (KURA), DiaMedica Therapeutics (DMCAF), Intra-Cellular Therapies (ITCI), Arvinas (ARVN), Stemline Therapeutics (STML), CannTrust (CTST), Zymeworks (ZYME), Myovant Sciences (MYOV), Organogenesis (ORGO), ZEALAND PHARMA/S (ZEAL) and Cytokinetics (CYTK).
What other stocks do shareholders of Kala Pharmaceuticals own?
Who are Kala Pharmaceuticals' key executives?
Kala Pharmaceuticals' management team includes the folowing people:
- Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 53)
- Mr. Todd Bazemore, Chief Operating Officer (Age 49)
- Dr. Kim Brazzell, Chief Medical Officer (Age 66)
- Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
- Ms. Mary Reumuth CPA, CPA, CFO & Treasurer (Age 44)
When did Kala Pharmaceuticals IPO?
(KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.
Who are Kala Pharmaceuticals' major shareholders?
Kala Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.35%), Matisse Capital (0.13%), Alambic Investment Management L.P. (0.12%), Marshall Wace LLP (0.12%), Hamilton Lane Advisors LLC (0.10%) and Rhumbline Advisers (0.06%). Company insiders that own Kala Pharmaceuticals stock include Associates LLC Cdk, Gregory Grunberg, Howard B Rosen, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Institutional Ownership Trends for Kala Pharmaceuticals.
Which major investors are selling Kala Pharmaceuticals stock?
Which major investors are buying Kala Pharmaceuticals stock?
KALA stock was purchased by a variety of institutional investors in the last quarter, including Matisse Capital, Alambic Investment Management L.P., Marshall Wace LLP, Boston Partners, Patriot Financial Group Insurance Agency LLC, Rhumbline Advisers and BNP Paribas Arbitrage SA. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Associates LLC Cdk, Gregory Grunberg, Howard B Rosen, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Kala Pharmaceuticals.
How do I buy shares of Kala Pharmaceuticals?
Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kala Pharmaceuticals' stock price today?
One share of KALA stock can currently be purchased for approximately $5.59.
How big of a company is Kala Pharmaceuticals?
Kala Pharmaceuticals has a market capitalization of $189.41 million. The company earns $-66,740,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. Kala Pharmaceuticals employs 130 workers across the globe.View Additional Information About Kala Pharmaceuticals.
What is Kala Pharmaceuticals' official website?
How can I contact Kala Pharmaceuticals?
Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]
MarketBeat Community Rating for Kala Pharmaceuticals (NASDAQ KALA)
MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
